A new Phase 3 clinical trial update for survodutide was recorded on August 21, 2026. The study, titled "A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar," is registered under identifier NCT07754461. According to ClinicalTrials.gov, the trial's current status is listed as recruiting.
Survodutide remains an unapproved compound under research and is not currently approved for medical use. The trial is designed to examine its potential in helping people with type 2 diabetes manage blood sugar levels, though no results have been posted at this stage. The Phase 3 designation indicates this is a later-stage study in the clinical development process.
This update reflects only the trial's registration status and recruitment phase as of the listed date. No efficacy or safety outcomes have been reported as part of this update. Readers interested in following the trial's progress can monitor the official ClinicalTrials.gov listing for updates on enrollment, completion, and eventual results.
For more background on survodutide, including its research history and regulatory status, see the compound overview.